Pfizer and BioNTech on Tuesday said they have begun submitting data to U.S. regulators seeking emergency use authorisation (EUA) of their Covid-19 vaccine for children under age 5, despite weaker than expected immune responses in their clinical trial of 2- to 4-year-olds.<br /><br />Read more at https://bit.ly/3ufBoZX<br /><br />WATCH MORE: https://thestartv.com/c/news<br />SUBSCRIBE: https://cutt.ly/TheStar<br />LIKE: https://fb.com/TheStarOnline<br />
